¿Cuáles son los nuevos medicamentos para el tratamiento de la psoriasis en placas?

The latest medicines to treat plaque psoriasis will be the interleukin-23 antagonists, which have been Food And Drug Administration authorized according to the brand names Skyrizi, Ilumya and Tremfya.

Interleukin-23 antagonists work by stopping interleukin-23 (IL-23), a pro-inflammatory cytokine considered to perform a major role in persistent immune-mediated conditions, such as plaque psoriasis.

Interleukin-23 antagonists are included in a broader band of drugs known as biologics. Biologics are administered via subcutaneous treatment or intravenous infusion and are also reserved for moderate to serious cases of psoriasis. Additional biologic drugs consist of tumefaction necrosis factor-alpha (TNF-alpha) blockers, interleukin 12 and 23 (IL-12/23) antagonists, and interleukin 17 (IL-17) antagonists.

General treatments, such as biologic treatment options, are merely useful psoriasis that has not answered to many other treatments (relevant treatments and phototherapy).

To learn more about some other psoriasis drugs, including relevant treatment options, see treatments for Psoriasis

New Treatments for Plaque Psoriasis – newest Food And Drug Administration Approvals

medication Administration Drug Class Patient Population Company Food And Drug Administration Approved for Psoriasis Psoriasis sign different Indications
Skyrizi (risankizumab-rzaa) subcutaneous treatment at days 0,  4, then every 12 months interleukin-23 antagonist grownups AbbVie Inc. 23-Apr-2019
  • moderate-to-severe plaque psoriasis
  • none
Cimzia (certolizumab pegol) subcutaneous injection every 2 weeks tumor necrosis aspect (TNF) blocker grownups UCB, Inc. 24-May-2018
  • moderate-to-severe plaque psoriasis
  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • non-radiographic axial spondyloarthritis
Ilumya (tildrakizumab-asmn) subcutaneous treatment at months 0, 4, next every 12 months interleukin-23 antagonist grownups Sun Pharmaceutical businesses, Inc. 20-Mar-2018
  • moderate-to-severe plaque psoriasis
  • none
Tremfya (guselkumab) subcutaneous treatment at days 0, 4, after that every 8 weeks interleukin-23 antagonist adults Janssen Biotech, Inc. 13-Jul-2017
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
Siliq (brodalumab) subcutaneous shot at weeks 0, 1, and 2, next every 2 weeks interleukin-17A antagonist grownups Bausch wellness organizations Inc. 15-Feb-2017
  • moderate-to-severe plaque psoriasis in patients that have didnt reply or have lost response to additional general therapies
  • none
Taltz (ixekizumab) subcutaneous shot at months 0, 2, 4, 6, 8, 10, and 12, subsequently every 30 days interleukin-17A antagonist grownups and kids 6 decades and earlier Eli Lilly and Company 22-Mar-2016
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • ankylosing spondylitis
  • non-radiographic axial spondyloarthritis
Cosentyx (secukinumab) subcutaneous shot at months 0, 1, 2, 3, and 4, subsequently every a month interleukin-17A antagonist adults Novartis Pharmaceuticals Corporation 21-Jan-2015
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • ankylosing spondylitis
  • non-radiographic axial spondyloarthritis
Otezla (apremilast) oral pills 2 times each day phosphodiesterase 4 (PDE4) inhibitor adults Celgene Corporation 23-Sep-2014
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • oral ulcers connected with Behçet’s Disease
Stelara (ustekinumab) subcutaneous injection at days 0 and 4, then every
12 days
interleukin-12 and -23 antagonist adults and kids 12 decades and more mature Janssen Biotech, Inc. 25-Sep-2009
  • moderate-to-severe plaque psoriasis
  • psoriatic arthritis
  • Crohns disease
  • ulcerative colitis
Humira (adalimumab) subcutaneous shot at days 0 and 1, after that every two weeks tumefaction necrosis factor (TNF) blocker grownups AbbVie Inc. 18-Jan-2008
  • moderate to serious chronic plaque psoriasis whenever different endemic treatments are clinically less appropriate
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • ulcerative colitis
  • hidradenitis suppurativa
  • uveitis
Remicade (infliximab) intravenous infusion at months 0, 2 and 6, next every 2 months tumefaction necrosis element (TNF) blocker grownups Janssen Biotech, Inc. 26-Sep-2006
  • chronic extreme plaque psoriasis when different systemic therapies are medically much less appropriate
  • rheumatoid arthritis
  • psoriatic arthritis
  • ankylosing spondylitis
  • Crohn’s disease
  • ulcerative colitis
Enbrel (etanercept) Adults: subcutaneous shot two times regular for a couple of months then as soon as regular
kids: subcutaneous injection when regular
tumefaction necrosis element (TNF) blocker grownups and children 4 decades and earlier Amgen Inc. 30-Apr-2004
  • chronic reasonable to extreme plaque psoriasis
  • rheumatoid arthritis
  • juvenile idiopathic arthritis
  • psoriatic arthritis
  • ankylosing spondylitis

The biosimilars for tumefaction necrosis aspect (TNF) blockers HumiraRemicade, and Enbrel may also be Food And Drug Administration authorized for the treatment of plaque psoriasis:

Humira (adalimumab) Biosimilars

Remicade (infliximab) Biosimilars

Enbrel (etanercept) Biosimilars

For facts, see Psoriasis: treatments to Manage Your problems & Facial Skin

author website:https://fildenasinreceta.com/